Sars Cov-2/COVID-19 in Multiple Myeloma Latin-American Patients Study on Behalf of GELAMM
Humberto Martínez Cordero, MD, Camila Peña, MD, Dorotea Fantl, MD, Eloisa Riva, MD, Natalia Paola Schutz, MD, Virginia Abello, MD, Guillermo Ruiz Arguelles, Aline Ramirez Alvarado, Lina Moreno Gómez, Alana Von Glasenapp, MD, Andrea Noboa, MD, Henry Idrobo, MD, Juan Ospina Idarraga, Christine Rojas, MD, Judith Pineda, Cristian Seehaus, MD, Guillermina Remaggi, MD, Sofia Sanchez, MD, Ramiro Espinoza, Martha Alvarado, Jose Antonio De la Peña-Celaya, Juan Manuel Perez, Luara L. Arana-Luna, MD, María Eugenia Espitia, Eleazar Hernandez, MD, Lourdes David Salas, Evelyn Herrera
The SARS CoV-2 / COVID 19 pandemic has challenged the world’s health systems, especially services that treat cancer. The first studies in China showed that cancer patients had a higher risk of becoming infected and dying. Other risk factors for mortality were age over 65 years, male sex, the presence of comorbidity, hypertension, cardiovascular disease, diabetes, and obesity. Data on the specific behavior of patients with multiple myeloma (MM) in the pandemic are scarce. The mechanisms by which MM patients may have a higher mortality are multiple, derived both from the disease itself due to cellular and humoral immunity deficiency as well as from anti-myeloma treatment. The present study aims to establish the behavior of the disease in the pandemic period in Latin America.